People
Sandra Horning, Roche’s chief medical officer and head of global product development, will retire from the company at the end of the year, leaving some big shoes to fill.
“It’s important to recognize that this problem is there and this problem is persisting over the years,” Kanwal Raghav, author of the study and an oncologist at MD Anderson Cancer Center, told STAT.
The data-manipulation scandal with Novartis is widening, undermining investors’ trust in company chief executive officer Vas Narasimhan.
When it comes to potential pricing controls of the pharmaceutical industry, Jim Greenwood, chief executive officer of BIO, grimly stated that “nothing good” was going on in the halls of power in Washington, D.C.
Jill Adler-Moore, a renowned microbiologist and professor emerita at Cal Poly Pomona, was honored for her research, leadership and years of mentorship during a Cal State LA BioSpace event celebrating emerging entrepreneurs.
Biopharma companies strengthen their executive ranks and boards with new additions.
According to a regulatory filing, Saunders will walk away with $14.9 million in cash and $23.6 million in equity, mostly stock based on performance.
In a brief announcement, AveXis said the Kaspar brothers have not been involved in any operations at AveXis since early May, seemingly ahead of the U.S. Food and Drug Administration’s approval of Zolgensma.
AgriMetis, LLC is pleased to announce that Dr. Andrew Plant joined the AgriMetis team as Chief Technology Officer (CTO) in July 2019.
Great Bay Bio, a leading AI biotechnology company dedicated to big data-driven CMC development of innovative biologics, is pleased to announce the establishment of its 3D Advisory Board.
PRESS RELEASES